Clinical experience with L-asparaginase.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001377:Azaserine / Q000009:adverse effects / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000188:drug therapy; D002493:Central Nervous System Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D004342:Drug Hypersensitivity; D004926:Escherichia coli / Q000201:enzymology*; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010195:Pancreatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
D001377:Azaserine; D015122:Mercaptopurine; D001215:Asparaginase; D008727:Methotrexate